Fenofibrate Capsule
NDC Package 72789-310-30

11-digit billing NDC: 72789031030 · Billing unit: EA · 30 EA per package

Package Information

Fenofibrate capsules is fenofibrate is contraindicated in patients with:Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis [see Clinical Pharmacology (12.3)].Active liver disease, including those with unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2)].Pre-existing gallbladder disease [see Warnings and Precautions (5.5)].Hypersensitivity to fenofibrate, fenofibric acid, or any of the excipients in fenofibrate capsules. This formulation utilizes a capsule delivery system. Marketed by Pd-rx Pharmaceuticals, Inc., this product is identified by NDC 72789-310 and is authorized under FDA application ANDA201748.

Identification & Billing

NDC Package Code
72789-310-30
Package Description
30 CAPSULE in 1 BOTTLE, PLASTIC
Product Code
11-Digit Billing Format
72789031030
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk
RxCUI: 483425 - fenofibrate 130 MG Oral Capsule

Clinical Specifications

Proprietary Name
Fenofibrate
Non-Proprietary Name
Fenofibrate
Substance Name
Fenofibrate
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Fenofibrate is contraindicated in patients with:Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis [see Clinical Pharmacology (12.3)].Active liver disease, including those with unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2)].Pre-existing gallbladder disease [see Warnings and Precautions (5.5)].Hypersensitivity to fenofibrate, fenofibric acid, or any of the excipients in fenofibrate capsules. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with fenofibrate [see Warnings and Precautions (5.9)].

Regulatory & Marketing

Labeler Name
Pd-rx Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA201748
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-02-2015
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72789-310-30 identifies a specific commercial package of 30 capsule in 1 bottle, plastic of Fenofibrate, a human prescription drug labeled by Pd-rx Pharmaceuticals, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This capsule is formulated for oral use and contains fenofibrate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Pd-rx Pharmaceuticals, Inc. on March 02, 2015. The current certification is valid through December 31, 2027.

How is this Pd-rx Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72789031030. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72789-310-30
11-Digit CMS (5-4-2)
72789-0310-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.